Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-
characterized genetic and molecular landscape, targeted therapies for AML have failed to …

Proteasome inhibition has been recognized as a novel treatment modality in hematologic
malignancies. Initially, the reversible proteasome inhibitor bortezomib demonstrated efficacy …

The intracellular concentration of proteins in both normal and tumor cells are regulated by
the balance between the rates of protein synthesis vs. degradation. The ubiquitin …

The ubiquitin–proteasome pathway is responsible for the vast majority of regulated
eukaryotic intracellular proteolysis. Inhibition of the proteasome induces beneficial …

Background: The ubiquitin-proteasome system has become a promising novel molecular
target in cancer due to its critical role in cellular protein degradation, its interaction with cell …

Many cellular processes converge on the proteasome, and its key regulatory role is
increasingly being recognized. Proteasome inhibition allows the manipulation of many …

Acute lymphoblastic leukaemia (ALL) is an aggressive haematolymphoid malignancy. The
prognosis of ALL is excellent in paediatric population, however the outcome of …

Background Proteasome inhibitors are anticancer compounds that disrupt the proteolytic
activity of the proteasome and lead to tumor cell growth arrest and apoptosis. Bortezomib is …

The proteasome is a multi-unit enzyme complex found in the cytoplasm and nucleus of all
eukaryotic cells and is responsible for degradation of unneeded or damaged intracellular …

Introduction: Proteasome inhibitors have garnered interest as novel chemotherapeutic
agents based on their ability to inhibit the growth of cancer cells by altering the balance of …